Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.

Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES.

J Cancer Res Clin Oncol. 2018 Sep 25. doi: 10.1007/s00432-018-2753-y. [Epub ahead of print]

PMID:
30255380
2.

Introducing Transthyretin as a Differentially Expressed Protein in Washing Subtype of Obsessive-Compulsive Disorder.

Azodi MZ, Tavirani MR, Oskouie AA, Mansouri V, Hamdieh M, Nejati N, Hamid-Pour M, Ahmadzadeh A, Rostami-Nejat M, Tavirani MR, Tabatabaei SAM.

Basic Clin Neurosci. 2018 May-Jun;9(3):187-194. doi: 10.29252/NIRP.BCN.9.3.187.

3.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.

Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD.

Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. doi: 10.1158/1078-0432.CCR-18-0864. Epub 2018 Jun 25.

PMID:
29941483
4.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.

Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE.

Reprod Sci. 2018 Jan 1:1933719118778801. doi: 10.1177/1933719118778801. [Epub ahead of print]

PMID:
29843577
5.

Laparoscopic Ligation of Uterine Vasculature for Fertility-Sparing Management of Postabortal Hemorrhage.

Menderes G, Leon-Martinez D, Azodi M.

J Minim Invasive Gynecol. 2018 Mar 30. pii: S1553-4650(18)30177-8. doi: 10.1016/j.jmig.2018.03.020. [Epub ahead of print]

PMID:
29609031
6.

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD.

J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27.

PMID:
29584549
7.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2018 Jun;149(3):585-591. doi: 10.1016/j.ygyno.2018.03.050. Epub 2018 Mar 21.

PMID:
29572027
8.

In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.

Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Mol Cancer Ther. 2018 May;17(5):1003-1011. doi: 10.1158/1535-7163.MCT-17-0930. Epub 2018 Feb 13.

PMID:
29440294
9.

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer.

Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE.

Gynecol Oncol Rep. 2018 Jan 9;23:28-33. doi: 10.1016/j.gore.2018.01.003. eCollection 2018 Feb.

10.

Amendment of Agricultural Soil with Metal Nanoparticles: Effects on Soil Enzyme Activity and Microbial Community Composition.

Asadishad B, Chahal S, Akbari A, Cianciarelli V, Azodi M, Ghoshal S, Tufenkji N.

Environ Sci Technol. 2018 Feb 20;52(4):1908-1918. doi: 10.1021/acs.est.7b05389. Epub 2018 Feb 8.

PMID:
29356510
11.

Minimally invasive abdominal cerclage compared to laparotomy: a comparison of surgical and obstetric outcomes.

Kim S, Hill A, Menderes G, Cross S, Azodi M, Bahtiyar MO.

J Robot Surg. 2018 Jun;12(2):295-301. doi: 10.1007/s11701-017-0726-9. Epub 2017 Jul 18.

PMID:
28721634
12.

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Oct;147(1):145-152. doi: 10.1016/j.ygyno.2017.07.009. Epub 2017 Jul 10.

13.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Clin Cancer Res. 2017 Oct 1;23(19):5836-5845. doi: 10.1158/1078-0432.CCR-16-2862. Epub 2017 Jul 5.

14.

Natural Orifice-Assisted Laparoscopic Meckel Diverticulectomy Incidentally Found During Para-Aortic Mass Resection.

Menderes G, Dugan K, Klein MJ, Azodi M.

J Minim Invasive Gynecol. 2018 Jan;25(1):19-20. doi: 10.1016/j.jmig.2017.04.015. Epub 2017 May 3.

PMID:
28478192
15.

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jul;146(1):179-186. doi: 10.1016/j.ygyno.2017.04.023. Epub 2017 May 1.

16.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.

Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Med Oncol. 2017 May;34(5):91. doi: 10.1007/s12032-017-0956-8. Epub 2017 Apr 10.

17.

Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma.

Deshmukh U, McAdow M, Black J, Hui P, Azodi M.

Gynecol Oncol Rep. 2017 Mar 6;20:54-57. doi: 10.1016/j.gore.2017.03.001. eCollection 2017 May.

18.

Dissolution Behavior of Silver Nanoparticles and Formation of Secondary Silver Nanoparticles in Municipal Wastewater by Single-Particle ICP-MS.

Azodi M, Sultan Y, Ghoshal S.

Environ Sci Technol. 2016 Dec 20;50(24):13318-13327. Epub 2016 Dec 6.

PMID:
27993044
19.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.

Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD.

Mol Cancer Ther. 2017 Feb;16(2):323-333. doi: 10.1158/1535-7163.MCT-16-0501. Epub 2016 Dec 12.

20.

Robot-Assisted Abdominal Cerclage During Pregnancy.

Zeybek B, Hill A, Menderes G, Borahay MA, Azodi M, Kilic GS.

JSLS. 2016 Oct-Dec;20(4). pii: e2016.00072.

21.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jan;144(1):146-152. doi: 10.1016/j.ygyno.2016.11.023. Epub 2016 Nov 26.

22.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

23.

Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.

Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES.

Gynecol Oncol. 2017 Jan;144(1):77-82. doi: 10.1016/j.ygyno.2016.09.027. Epub 2016 Oct 24.

PMID:
27789084
24.

Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer.

Gojayev A, English DP, Macer M, Azodi M.

Case Rep Obstet Gynecol. 2016;2016:8547173. Epub 2016 Sep 25.

25.

The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy.

Hill AM, Davis KM, Clark-Donat L, Hammons LM, Azodi M, Silasi DA.

J Minim Invasive Gynecol. 2017 Jan 1;24(1):108-113. doi: 10.1016/j.jmig.2016.09.015. Epub 2016 Oct 1.

PMID:
27702701
26.

The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy.

Tower AM, Clark Donat L, Azodi M, Silasi DA.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S77. doi: 10.1016/j.jmig.2015.08.205. Epub 2015 Oct 15. No abstract available.

PMID:
27679335
27.

Identifying Risk Factors for Urinar y Retention After Hysterectomy for Leiomyoma.

Clark Donat L, Tower A, Clark M, Silasi DA, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S59. doi: 10.1016/j.jmig.2015.08.157. Epub 2015 Oct 15. No abstract available.

PMID:
27679285
28.

Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival?

Clark M, Glasgow M, Menderes G, Azodi M, Silasi DA.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S48-S49. doi: 10.1016/j.jmig.2015.08.134. Epub 2015 Oct 15. No abstract available.

PMID:
27679256
29.

Comparison of Robotics Versus Conventional Laparoscopy for Management of Benign Adnexal Masses.

Zigras T, Goodman L, Menderes G, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S22-S23. doi: 10.1016/j.jmig.2015.08.069. Epub 2015 Oct 15. No abstract available.

PMID:
27679091
30.

Laparoscopic Ovarian Transposition.

Kakar F, English D, Menderes G, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S153. doi: 10.1016/j.jmig.2015.08.566. Epub 2015 Oct 15. No abstract available.

PMID:
27678870
31.

Techniques for Removing Pelvic Masses.

Clark Donat L, Tower AM, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S146. doi: 10.1016/j.jmig.2015.08.520. Epub 2015 Oct 15. No abstract available.

PMID:
27678815
32.

Pararectal Space Dissection for Treatment of Endometriosis.

Tower AM, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S138. doi: 10.1016/j.jmig.2015.08.461. Epub 2015 Oct 15. No abstract available.

PMID:
27678755
33.

Combined Natural Orifice Single-Site Hysterectomy.

Tower AM, Schwab C, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S127. doi: 10.1016/j.jmig.2015.08.389. Epub 2015 Oct 15. No abstract available.

PMID:
27678681
34.

An Extra Step to Prevent Troublesome Uterine Artery Bleeding: Retroperitoneal Dissection and Ligation of the Uterine Artery at the Source.

Tower AM, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S127. doi: 10.1016/j.jmig.2015.08.391. Epub 2015 Oct 15. No abstract available.

PMID:
27678679
35.

The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer.

Menderes G, Black JD, Azodi M.

Expert Rev Anticancer Ther. 2016 Sep;16(9):899-901. doi: 10.1080/14737140.2016.1219658. Epub 2016 Aug 9. No abstract available.

PMID:
27477495
36.

Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients.

Stahl JM, Park HS, Silasi DA, Azodi M, Damast S.

Pract Radiat Oncol. 2016 Jul-Aug;6(4):226-32. doi: 10.1016/j.prro.2015.09.015.

PMID:
27364883
37.

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.

Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Br J Cancer. 2016 Jul 26;115(3):303-11. doi: 10.1038/bjc.2016.198. Epub 2016 Jun 28.

38.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.

Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD.

Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2.

39.

Incidental injury and repair of obturator nerve during laparoscopic pelvic lymphadenectomy.

Menderes G, Vilardo N, Schwab CL, Azodi M.

Gynecol Oncol. 2016 Jul;142(1):208. doi: 10.1016/j.ygyno.2016.05.023. Epub 2016 May 27.

PMID:
27234143
40.

Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.

Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE.

Eur J Gynaecol Oncol. 2016;37(2):199-203.

PMID:
27172745
41.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Br J Cancer. 2015 Dec 1;113(11):1641. doi: 10.1038/bjc.2015.388. No abstract available.

42.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.

Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

J Exp Clin Cancer Res. 2015 Oct 17;34:123. doi: 10.1186/s13046-015-0241-7.

43.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.

Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD.

Mol Cancer Ther. 2015 Nov;14(11):2519-26. doi: 10.1158/1535-7163.MCT-15-0383. Epub 2015 Sep 2.

44.

Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer: A Single Institution Retrospective Study of 47 Cases and Review of the Literature.

Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S.

Int J Gynecol Cancer. 2015 Nov;25(9):1711-6. doi: 10.1097/IGC.0000000000000554. Review. Erratum in: Int J Gynecol Cancer. 2016 Feb;26(2):422. Damast, Shari [added].

45.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Br J Cancer. 2015 Sep 29;113(7):1020-6. doi: 10.1038/bjc.2015.306. Epub 2015 Sep 1. Erratum in: Br J Cancer. 2015 Dec 1;113(11):1641.

46.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Am J Obstet Gynecol. 2016 Jan;214(1):99.e1-8. doi: 10.1016/j.ajog.2015.08.011. Epub 2015 Aug 10.

47.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD.

Gynecol Oncol. 2015 Oct;139(1):112-7. doi: 10.1016/j.ygyno.2015.08.002. Epub 2015 Aug 8.

48.

Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics.

Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ.

Gynecol Obstet Invest. 2015 Jun 6. [Epub ahead of print]

PMID:
26067608
49.

Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.

Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Int J Cancer. 2015 Dec 1;137(11):2618-29. doi: 10.1002/ijc.29632. Epub 2015 Aug 18.

50.

Transvaginal morcellation.

Clark Donat L, Clark M, Tower AM, Menderes G, Parkash V, Silasi DA, Azodi M.

JSLS. 2015 Apr-Jun;19(2). pii: e2014.00255. doi: 10.4293/JSLS.2014.00255.

Supplemental Content

Support Center